Dr. Reddy's Laboratories Limited American Depositary Shares RDY

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Con 80 acciones de RDY (USD 999,60) habrías recibido USD 6,40 en dividendos en los últimos 12 meses.

RDY hizo una división de acciones (split) de 5:1 el 5 de noviembre de 2024: cada acción se convirtió en 5. Cambió la cantidad de acciones y su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 2 oct

  Global Substance Use Disorder Treatment Market Analysis and Forecast to 2030 | Long-Acting Therapies, Telemedicine, and Drug Innovation Drive Growth

  The global substance use disorder treatment market is projected to grow from $11.6 billion in 2025 to $14.6 billion by 2030, with a compound annual growth rate of 4.6%. Growth is driven by long-acting therapies, telemedicine expansion, drug innovation, and increased government interventions, though challenges include low treatment penetration and stigma.

  

• GlobeNewswire Inc. 22 sept

  INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Limited - RDY

  Pomerantz LLP is investigating potential securities fraud claims against Dr. Reddy's Laboratories following the company's announcement of weak Q1 FY2027 earnings with only $0.06 EPS, attributed to a ₹2.4 billion provision for out-of-specification semaglutide batches. The disclosure triggered a 9.4% stock price decline on July 22, 2026.

  

• GlobeNewswire Inc. 22 sept

  INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS

  Pomerantz LLP announced investigations into potential securities fraud at Emergent BioSolutions, Klarna Group, and Dr. Reddy's Laboratories. Emergent reported a $191.3 million impairment charge on its NARCAN asset group and cut full-year revenue guidance by 10.8%, citing increased competitive intensity. The stock fell 29.58% on the news.

  

• GlobeNewswire Inc. 31 ago

  Papulopustular Rosacea Market Report Now Available, Covers 11 Countries Across North America, Europe, and Asia-Pacific, Profiling Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Laboratories

  The global papulopustular rosacea market is projected to grow steadily through 2035, driven by rising prevalence, improved diagnosis, and demand for safer non-antibiotic treatments. Advanced therapies including topical ivermectin, azelaic acid, and minocycline foam are reshaping care. Key players include Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Laboratories, with growth supported by dermatology R&D, innovative drug delivery, and telemedicine despite challenges like high treatment costs and underdiagnosis.

  

• GlobeNewswire Inc. 5 ago

  DR. REDDY’S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

  Law firm Kirby McInerney LLP is investigating potential securities fraud claims against Dr. Reddy's Laboratories following the company's disclosure of a ₹2.4 billion provision for out-of-spec semaglutide batches in Q1 FY2027 earnings. The stock fell 9% on the news, though management stated there was no patient safety impact or regulatory filing impact.